YAP1 Mediates Initial Cell Survival during Lorlatinib Treatment via AKT Signaling in ROS1-Rearranged Lung Cancer

Scientists clarified the initial survival mechanisms of tumor cells in NSCLC during treatment with lorlatinib, a ROS proto-oncogene 1 (ROS1) tyrosine kinase inhibitor.